FOLR2 and ovarian carcinoma: Supporting the translatability of this CAR-T cell-based approach to humans, our results demonstrated the presence of M2-like FRβ+ TAMs in ascite samples from ovarian cancer patients, as well as the feasibility of their targeting with hFRβ CAR-T cells.